文献速递前列腺癌

微超声引导与多参数磁共振靶向前列腺穿刺活检诊断前列腺癌的系统评价与荟萃分析

Micro-Ultrasound-Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2021-02-12

该系统评价与荟萃分析比较微超声引导与多参数磁共振靶向前列腺穿刺活检对前列腺癌的检出率,纳入18项研究(定量合成13项,1125名参与者)。结果显示两种方法在各病理分级前列腺癌检出率相似,微超声引导可作为多参数磁共振靶向活检的替代选择,但需高质量随机试验证实。

要点

  • 微超声与多参数磁共振靶向活检对前列腺癌的检出率相似。
  • ISUP分级≥2前列腺癌的合并检出比为1.05(95%CI 0.93-1.19)。
  • 微超声引导可作为多参数磁共振靶向活检的潜在替代方案。

核心结论

  • 微超声引导前列腺穿刺活检对前列腺癌的诊断检出率与多参数磁共振靶向活检相当。
  • 微超声引导可被视为多参数磁共振靶向活检的有吸引力的替代方案。
  • 仍需高质量随机试验来证实这些发现。

研究设计与样本

  • 系统评价与荟萃分析,比较微超声引导与多参数磁共振靶向前列腺穿刺活检的诊断准确性(PROSPERO ID: CRD42020198326)。
  • 检索PubMed、Scopus和Cochrane Library数据库及灰色文献至2020年11月30日。
  • 纳入18项研究进行定性合成,13项进行定量合成;定量合成中1125名参与者接受了微超声引导后多参数磁共振靶向及系统前列腺穿刺活检。

主要发现

  • 微超声与多参数磁共振靶向前列腺穿刺活检在所有前列腺癌分级中显示出相似的检出率。
  • ISUP分级≥2前列腺癌的合并检出比为1.05(95% CI 0.93-1.19, I2=0%)。
  • ISUP分级≥3前列腺癌的合并检出比为1.25(95% CI 0.95-1.64, I2=0%)。
  • 临床不显著(ISUP分级1)前列腺癌的合并检出比为0.94(95% CI 0.73-1.22, I2=0%)。
  • 前列腺癌总体检出比为0.99(95% CI 0.89-1.11, I2=0%)。

关键数值与推荐

  • 微超声与多参数磁共振靶向活检对ISUP分级≥2前列腺癌的检出比1.05(95% CI 0.93-1.19, I2=0%)。
  • 对ISUP分级≥3前列腺癌的检出比1.25(95% CI 0.95-1.64, I2=0%)。
  • 对临床不显著(ISUP分级1)前列腺癌的检出比0.94(95% CI 0.73-1.22, I2=0%)。
  • 对前列腺癌总体的检出比0.99(95% CI 0.89-1.11, I2=0%)。

临床怎么用

  • 微超声引导前列腺穿刺活检可作为多参数磁共振靶向活检的替代方案,尤其在不具备磁共振靶向条件时。
  • 临床决策中应考虑微超声引导活检与磁共振靶向活检检出率相当的证据。
  • 鉴于证据局限性,实施前应结合本地经验和患者具体情况。

局限性

  • 需要高质量随机试验来证实本荟萃分析的发现。
  • 定量合成仅纳入13项研究,样本量有限。
  • 检索截止至2020年11月30日,后续研究未纳入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Micro-ultrasound is a novel high resolution ultrasound technology aiming to improve prostate imaging and, consequently, the diagnostic accuracy of ultrasound-guided prostate biopsy. Micro-ultrasound-guided prostate biopsy may present comparable detection rates to the standard of care multiparametric magnetic resonance imaging-targeted prostate biopsy for the diagnosis of clinically significant prostate cancer. We aimed to compare the detection rate of micro-ultrasound vs multiparametric magnetic resonance imaging-targeted prostate biopsy for prostate cancer diagnosis. MATERIALS AND METHODS: We performed a systematic review and meta-analysis of diagnostic accuracy studies comparing micro-ultrasound-guided prostate biopsy to multiparametric magnetic resonance imaging-targeted prostate biopsy as a reference standard test (PROSPERO ID: CRD42020198326). Records were identified by searching in PubMed®, Scopus® and Cochrane Library databases, as well as in potential sources of gray literature until November 30th, 2020. RESULTS: We included 18 studies in the qualitative and 13 in the quantitative synthesis. In the quantitative synthesis, 1,125 participants received micro-ultrasound-guided followed by multiparametric magnetic resonance imaging-targeted and systematic prostate biopsy. Micro-ultrasound and multiparametric magnetic resonance imaging-targeted prostate biopsies displayed similar detection rates across all prostate cancer grades. The pooled detection ratio for International Society of Urological Pathology Grade Group ≥2 prostate cancer was 1.05 (95% CI 0.93-1.19, I2=0%), 1.25 (95% CI 0.95-1.64, I2=0%) for Grade Group ≥3 and 0.94 (95% CI 0.73-1.22, I2=0%) for clinically insignificant (Grade Group 1) prostate cancer. The overall detection ratio for prostate cancer was 0.99 (95% CI 0.89-1.11, I2=0%). CONCLUSIONS: Micro-ultrasound-guided prostate biopsy provides comparable detection rates for prostate cancer diagnosis with the multiparametric magnetic resonance imaging-guided prostate biopsy. Therefore, it could be considered as an attractive alternative to multiparametric magnetic resonance imaging-targeted prostate biopsy. Nevertheless, high quality randomized trials are warranted to corroborate our findings.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sountoulides P, Pyrgidis N, Polyzos SA, et al. Micro-Ultrasound-Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. J Urol. 2021. PMID: 33577367. doi:10.1097/JU.0000000000001639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。